Involvement of NF-κB in mediating the anti-tumour effects of combretastatins in T cells Jade K. PollockLisa M. GreeneDaniela M. Zisterer PRECLINICAL STUDIES 19 February 2018 Pages: 523 - 535
MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping S. Betty YanSuzane L. UmRichard A. Walgren PRECLINICAL STUDIES Open access 29 November 2017 Pages: 536 - 544
Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer associated fibroblasts (CAFs) by synergistic induction of apoptosis Hak-Min LeeEunmyong LeeSeok-Hyung Kim PRECLINICAL STUDIES 18 January 2018 Pages: 545 - 560
Development of a dietary formulation of the SHetA2 chemoprevention drug for mice Doris M. BenbrookNaveena B. JanakiramChinthalapally V. Rao PRECLINICAL STUDIES Open access 22 December 2017 Pages: 561 - 570
Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway Jianan ZhouCanjing ZhangBobin Chen PRECLINICAL STUDIES 05 March 2018 Pages: 571 - 580
The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells Alexandra CanoniciZulfiqar QadirJohn Crown PRECLINICAL STUDIES 02 February 2018 Pages: 581 - 589
Repurposing of the CDK inhibitor PHA-767491 as a NRF2 inhibitor drug candidate for cancer therapy via redox modulation Hsiu-Yu LiuAndrea Z. TuckettJohannes L. Zakrzewski PRECLINICAL STUDIES 03 January 2018 Pages: 590 - 600
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept Rivka R. ColenTakeo FujiiAung Naing PHASE I STUDIES 27 October 2017 Pages: 601 - 607
Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations Motohiro TamiyaAkihiro TamiyaTomonori Hirashima PHASE I STUDIES 04 November 2017 Pages: 608 - 614
Combined treatment with pemetrexed and vinflunine in patients with metastatic urothelial cell carcinoma after prior platinum-containing chemotherapy – results of an exploratory phase I study H. PappotH. von der Maaseon behalf of NUCOG - Nordic Urothelial Cancer Oncology Group (NUCOG) PHASE I STUDIES 28 October 2017 Pages: 615 - 618
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors Rastislav BahledaMarie-Cécile Le DeleyJean-Charles Soria PHASE I STUDIES 02 November 2017 Pages: 619 - 628
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer Jonathan W. GoldmanLee S. RosenAmita Patnaik PHASE I STUDIES Open access 01 December 2017 Pages: 629 - 637
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience Takeo FujiiRivka R. ColenAung Naing PHASE I STUDIES 21 November 2017 Pages: 638 - 646
A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors Hideki UenoShunsuke KondoHaruyasu Murakami PHASE I STUDIES 17 February 2018 Pages: 647 - 656
Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition Margaret T. KasnerRosemarie MickAlexander E. Perl PHASE II STUDIES 02 April 2018 Pages: 657 - 666
A phase I/II trial of pemetrexed plus radiotherapy in elderly patients with locally advanced non-small cell lung cancer Akihiro TamiyaMasahiro MorimotoShinji Atagi PHASE II STUDIES 23 March 2018 Pages: 667 - 673
A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma Arthur LuiKaren MulderJennifer Spratlin PHASE II STUDIES 04 May 2018 Pages: 674 - 682
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies Herbert HurwitzEric Van CutsemEileen M. O’Reilly PHASE III STUDIES 06 March 2018 Pages: 683 - 695
Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer Motohiro TamiyaHidekazu SuzukiTomonori Hirashima PHASE III STUDIES 14 March 2018 Pages: 696 - 701
Unique characteristics of regulatory approval and pivotal studies of orphan anticancer drugs in Japan Hiroki NakayamaKatsura Tsukamoto PHASE III STUDIES 17 April 2018 Pages: 702 - 708
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients Teresa Di DesideroPaola OrlandiGuido Bocci SHORT REPORT 27 February 2018 Pages: 709 - 714
Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation Midori TanakaHidenobu IshiiTomoaki Hoshino SHORT REPORT 15 March 2018 Pages: 715 - 717
Autophagy inhibition improves the chemotherapeutic efficacy of cruciferous vegetable-derived diindolymethane in a murine prostate cancer xenograft model Hossam DrazAlexander A. GoldbergJ. Thomas Sanderson SHORT REPORT 02 April 2018 Pages: 718 - 725
Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer Yoshihisa NakataniHisato KawakamiShuji Arima SHORT REPORT 06 April 2018 Pages: 726 - 731
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis Jihoon KangInhwan HwangBaek-Yeol Ryoo SHORT REPORT 03 April 2018 Pages: 732 - 741
